Please login to the form below

Not currently logged in
Email:
Password:

Wyeth withdraws Pristiqs application

Wyeth Pharmaceuticals has withdrawn a marketing application for Pristiqs from the European Medicines Agency, it announced on March 12

Wyeth Pharmaceuticals has withdrawn a marketing application for Pristiqs from the European Medicines Agency (EMEA), it announced on March 12.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) raised questions about the risk-benefit profile of Pristiqs (desvenlafaxine) as a treatment for menopausal vasomotor symptoms (hot flashes).

The company now intends to carry out further studies and continue the development of the drug as a potential treatment.

Dr Gary Stiles, executive vice president and chief medical officer of Wyeth Pharmaceuticals, said: "We believe that desvenlafaxine can provide women with a non-hormonal option to treat vasomotor symptoms, and Wyeth remains committed to developing the molecule for this indication."

"Some of the questions raised by the CHMP can be addressed with our planned clinical trails, including the 12 month study Wyeth is initiating with post-menopausal women early this year," he added.

The original European marketing authorisation was submitted on 4 October 2006 and Pristiqs was under CHMP review at the time Wyeth withdrew the application.

Details and scientific data about the trails will be made published in a question-and-answer document together with the withdrawal letter by the EMEA in due course.

12th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics